TrialJournal of Crohn's & colitis2024

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.